Literature DB >> 30599401

Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators.

A Fassio1, G Adami2, D Gatti2, G Orsolini2, A Giollo2, L Idolazzi2, C Benini2, E Vantaggiato2, M Rossini2, O Viapiana2.   

Abstract

OBJECTIVE: Dicckopf-1 (Dkk-1) is a potent inhibitor of the Wnt canonical pathway. In rheumatoid arthritis (RA), Dkk-1 is upregulated by tumor necrosis factor-α (TNF). Certolizumab pegol (CMZ) is a biologic TNF-inhibitor (TNFi) effective in RA and slows radiographic progression. Data on the immediate effects (≤1-8 weeks) of TNFi on Wnt modulators are lacking. This study investigated the acute influence of TNFi treatment on Wnt modulators (Dkk-1 and sclerostin) and bone turnover markers (BTM), including intact N-terminal propeptide of collagen type I (PINP) and C-terminal telopeptide of type I collagen (CTX-I).
METHODS: This longitudinal, uncontrolled study involved female RA patients with inadequate response to conventional methotrexate who underwent treatment with CMZ. ESR, Dkk-1, sclerostin, BTM, parathyroid hormone (PTH), and 25OH-vitamin D levels were evaluated at baseline, week 1, week 4, and week 8. Radiographs of the hands and feet were obtained at baseline and the total and erosion scores were assessed using the Simple Erosion Narrowing Score method (SENS).
RESULTS: Seventeen patients were enrolled. Dkk-1 and CTX-I significantly decreased after one week of treatment with CMZ (-49.1 ± 17.1% and -25.0 ± 20.6%, respectively, p < 0.01), whereas PINP increased (+43.2 ± 31.5%, p < 0.01). These changes persisted at week 4 and 8.
CONCLUSIONS: Our study showed that TNF-alpha inhibition with CMZ promptly results in a rapid decline of serum Dkk-1 levels, alongside decreased bone resorption and increased bone formation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-TNF; Bone turnover markers; Certolizumab pegol; DKK-1; Dicckopf-1; Erosions; Rheumatoid arthritis; Wnt

Mesh:

Substances:

Year:  2018        PMID: 30599401     DOI: 10.1016/j.intimp.2018.12.050

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  Dickkopf-1 perpetuated synovial fibroblast activation and synovial angiogenesis in rheumatoid arthritis.

Authors:  Li Zheng; Fanlei Hu; Wenjie Bian; Yingni Li; Linqi Zhang; Lianjie Shi; Xiaoxu Ma; Yanying Liu; Xuewu Zhang; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2021-05-19       Impact factor: 2.980

2.  Immunoexpression of canonical Wnt and NF-κB signaling pathways in the temporomandibular joint of arthritic rats.

Authors:  Luane Macêdo de Sousa; Joana Maria Dos Santos Alves; Conceição da Silva Martins; Karuza Maria Alves Pereira; Paula Goes; Delane Viana Gondim
Journal:  Inflamm Res       Date:  2019-08-01       Impact factor: 4.575

Review 3.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

Review 4.  Osteoporosis in Rheumatic Diseases.

Authors:  Giovanni Adami; Angelo Fassio; Maurizio Rossini; Cristian Caimmi; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

Review 5.  Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Daniela Cici; Addolorata Corrado; Cinzia Rotondo; Francesco P Cantatore
Journal:  Int J Mol Sci       Date:  2019-11-07       Impact factor: 5.923

Review 6.  Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons.

Authors:  Irene Llorente; Noelia García-Castañeda; Cristina Valero; Isidoro González-Álvaro; Santos Castañeda
Journal:  Front Med (Lausanne)       Date:  2020-11-23

7.  Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker.

Authors:  Angelo Fassio; Giovanni Adami; Luca Idolazzi; Alessandro Giollo; Ombretta Viapiana; Emma Bosco; Riccardo Negrelli; Elena Sani; Damiano Sandri; Alessandro Mantovani; Giovanni Targher; Maurizio Rossini; Davide Gatti
Journal:  Calcif Tissue Int       Date:  2020-10-12       Impact factor: 4.333

Review 8.  The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.

Authors:  Eugenia Bertoldo; Giovanni Adami; Maurizio Rossini; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti; Angelo Fassio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-21       Impact factor: 5.555

9.  Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.

Authors:  Cem Gabay; Gerd R Burmester; Vibeke Strand; Jérôme Msihid; Moshe Zilberstein; Toshio Kimura; Hubert van Hoogstraten; Susan H Boklage; Jonathan Sadeh; Neil M H Graham; Anita Boyapati
Journal:  Arthritis Res Ther       Date:  2020-04-07       Impact factor: 5.156

10.  Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan.

Authors:  Shin-Ya Kawashiri; Yushiro Endo; Ayako Nishino; Momoko Okamoto; Sosuke Tsuji; Ayuko Takatani; Toshimasa Shimizu; Remi Sumiyoshi; Tomohiro Koga; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Toshiyuki Aramaki; Yukitaka Ueki; Tamami Yoshitama; Nobutaka Eiraku; Naoki Matsuoka; Akitomo Okada; Keita Fujikawa; Hiroaki Hamada; Shuji Nagano; Yoshifumi Tada; Atsushi Kawakami
Journal:  BMC Musculoskelet Disord       Date:  2021-06-01       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.